| Description | This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize Discoidin domain receptor tyrosine kinase 1. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | IF |
| Application Notes | The antibody is recommended for detection of DDR1 by IF assay. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | DDR1 |
| Alternative Name | DDR1; discoidin domain receptor tyrosine kinase 1; CAK; DDR; NEP; HGK2; PTK3; RTK6; TRKE; CD167; EDDR1; MCK10; NTRK4; PTK3A; epithelial discoidin domain-containing receptor 1; tyrosine kinase DDR; cell adhesion kinase; mammary carcinoma kinase 10; tyrosine-protein kinase CAK; protein-tyrosine kinase RTK-6; neuroepithelial tyrosine kinase; PTK3A protein tyrosine kinase 3A; CD167 antigen-like family member A; neurotrophic tyrosine kinase, receptor, type 4 |
| Gene ID | 780 |
| UniProt | Q08345 |
| Research Area | Neuroscience; Cancer Research |
| Related Disease | Cancer |
Figure 1 Recombinant Anti-DDR1 Antibody (V3S-0522-YC5759) in SDS-PAGE.
Lane 1: Non-Reduced Antibody
Lane 2: Reduced Antibody
Figure 1 Recombinant Anti-DDR1 Antibody (V3S-0522-YC5759) in SDS-PAGE.
Figure 2 Recombinant Anti-DDR1 Antibody (V3S-0522-YC5759) in SEC-HPLC.
The purity of V3S-0522-YC5759 was 99.0621% as determined by SEC-HPLC.
Figure 2 Recombinant Anti-DDR1 Antibody (V3S-0522-YC5759) in SEC-HPLC.
Figure 3 Recombinant Anti-DDR1 Antibody (V3S-0522-YC5759) in ELISA.
ELISA analysis of V3S-0522-YC5759 was performed by coating with human DRR1 protein.
The secondary antibody: HRP-conjugated goat anti-human IgG
Figure 3 Recombinant Anti-DDR1 Antibody (V3S-0522-YC5759) in ELISA.
Figure 4 Recombinant Anti-DDR1 Antibody (V3S-0522-YC5759) in Western Blot.
Western blot analysis of V3S-0522-YC5759 was performed by loading human DDR1 protein onto a 12% Tris-HCl polyacrylamide gel.
V3S-0522-YC5759 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-conjugated goat anti-human IgG
Lane 1: Reduced antigen (0.1 μg)
Lane 2: Reduced antigen (0.3 μg)
Lane 3: Reduced antigen (0.6 μg)
Figure 4 Recombinant Anti-DDR1 Antibody (V3S-0522-YC5759) in Western Blot.
